Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial Soria, J. C., Goldman, J. W., Wakelee, H., Gadgeel, S., Camidge, D. R., Solomon, B., Yu, H., Oxnard, G. R., Ou, S. H., Papadimitrakopoulou, V., Perol, M., Reckamp, K., Varga, A., Dziadziuszko, R., Chouaid, C., Cortot, A., Do, P., Moro-Sibilot, D., Poudenx, M., Sequist, L. V. ELSEVIER SCI LTD. 2015: S637

View details for DOI 10.1016/S0959-8049(16)31746-4

View details for Web of Science ID 000361887403063